利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.032 秒)

    MVA vaccine for delivery of a UL128 complex and preventing CMV infection
    1.
    发明授权
    MVA vaccine for delivery of a UL128 complex and preventing CMV infection 有权

    公开(公告)号：US10376575B2

    公开(公告)日：2019-08-13

    申请号：US15919110

    申请日：2018-03-12

    申请人： CITY OF HOPE

    发明人： Don J. Diamond ,  Felix Wussow

    IPC分类号： C12N7/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  C07K14/005

    摘要： In one embodiment, an expression system for expressing a UL128 complex is provided herein. The expression system may include a bacterial artificial chromosome (BAC) construct, wherein the BAC construct comprises a viral vector inserted with a set of DNA sequences that encode a UL128 complex. In another embodiment, a vaccine composition for preventing HCMV infection is provided. The vaccine composition may include a viral or bacterial vector capable of expressing a UL128 complex and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof or additional vector expressing a protein adjuvant. The viral vector may be an MVA and the UL128 complex includes five HCMV proteins or antigenic fragments thereof: UL128, UL130, UL131A, gL, and gH. In some embodiments, the viral vector is further inserted with one or more additional DNA sequences that encode one or more additional HCMVHCMV proteins or antigenic fragments thereof such as pp65, gB or both, or such as gM/gN or gO.

    MVA-gH/gL-PC vaccine derived antibodies neutralizing human cytomegalovirus infectivity and methods thereof
    6.
    发明授权
    MVA-gH/gL-PC vaccine derived antibodies neutralizing human cytomegalovirus infectivity and methods thereof 有权

    公开(公告)号：US11384137B2

    公开(公告)日：2022-07-12

    申请号：US16680205

    申请日：2019-11-11

    申请人： CITY OF HOPE

    发明人： Don J. Diamond ,  Flavia Chiuppesi ,  Felix Wussow

    IPC分类号： C07K16/08 ,  A61K39/12 ,  A61P31/22 ,  C07K7/06 ,  C07K7/08 ,  G01N33/569 ,  A61K39/00

    摘要： Vaccine-derived neutralizing antibodies (NAbs) for CMV infections and small peptides which define precise recognition elements of the antigens by the NAbs. The vaccine-derived NAbs may be produced by immunizing a subject with a gH/gL/UL128/UL130/UL131A pentameric glycoprotein complex (gH/gLPC). The vaccine-derived NAbs may have properties similar or identical to those of NAbs induced in a subject naturally infected with CMV. Native and non-native small peptides from UL128 and gH have been defined by mapping epitopes and deriving artificial sequences which are minimal recognition elements of vaccine-derived NAbs. These small peptides can be used to elicit vaccine-derived NAbs that prevent CMV entry into susceptible cell types and protect humans from infection and disease. Multivalent vaccines comprising these small peptides and/or epitopes as well as methods of using the vaccine-derived NAbs and small peptides for treating or preventing CMV infection in a subject are also provided.